AnneWoodBeavenMD
Oncology • Chapel Hill, NCCutaneous Lymphoma, Hematologic Oncology
Director of Lymphoma Program, Associate Professor of Medicine
Dr. Beaven is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
101 Manning Dr
Chapel Hill, NC 27514Phone+1 919-966-6759Fax+1 919-966-7772- Is this information wrong?
Summary
- Dr. Beaven cares for patients with all types of lymphoma, with a particular interest in T cell lymphoma. Along with Dr. Edith Bowers in dermatology, she runs a multidisciplinary Cutaneous lymphoma clinic.(https://unclineberger.org/patientcare/programs/lymphoma/cutaneous)
Her main area of research is the development of CarT clinical trials. The CD30 CarT trials are for patients with relapsed/refractory CD30+ lymphomas, which include Hodgkin lymphoma as well as some systemic T cell lymphomas such as anaplastic large cell lymphoma, and some cutaneous T cell lymphomas. In the near future they plan to open trials in both indolent and aggressive B cell lymphomas as well.
https://unclineberger.org/people/profiles/anne-beaven
Education & Training
University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2004 - 2007- University of North Carolina HospitalsResidency, Internal Medicine, 2000 - 2004
University of North Carolina at Chapel Hill School of MedicineClass of 2000
Certifications & Licensure
NC State Medical License 2003 - 2024- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL Start of enrollment: 2016 Aug 26
- CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma Start of enrollment: 2019 Sep 17
- Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma Start of enrollment: 2023 Sep 08
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 1 citationsAnti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30lymphoma: a phase 1 study.Natalie S Grover, George Hucks, Marcie L Riches, Anastasia Ivanova, Dominic T Moore, Thomas C Shea, Mary Beth Seegars, Paul M Armistead, Kimberly A Kasow, Anne W Beave...> ;The Lancet. Haematology. 2024 Mar 28
- The optimal management of relapsed and refractory Hodgkin lymphoma: post-brentuximab and checkpoint inhibitor failure.Grover, N., Dittus, C., Thakkar, A., Beaven, A.> ;Hematology. American Society of Hematology. Education Program. 2023 Dec 8
- 1 citationsPatient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas.Nicholas P Tschernia, Hillary Heiling, Allison M Deal, Catherine Cheng, Caroline Babinec, Megan Gonzalez, J Kaitlin Morrison, Christopher Dittus, Gianpietro Dotti, Ann...> ;Journal for Immunotherapy of Cancer. 2023 Aug 1
- Join now to see all
Abstracts/Posters
- Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin LymphomaAnne Beaven, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- High Risk Cytogenetic and Immunohistochemistry Findings in Monomorphic Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplant _ a Single Center ...Anne Beaven, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
'Nursing Is Dangerous': What We Heard This WeekJune 19th, 2020
Stand up to Cancer Dream Team Tackles T-cell Lymphoma, Focused on CAR-Based StrategiesJanuary 28th, 2019
NCCN Awards Grants to Three Researchers to Investigate Volasertib in Hematologic MalignanciesFebruary 10th, 2016
Professional Memberships
- Member
Other Languages
- Spanish
Hospital Affiliations
University of North Carolina HospitalsChapel Hill, North Carolina
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
